Is there strong evidence that bioidentical hormones work better than standard HT?

The short version: the evidence reviewed here does not answer whether bioidentical hormones work better than standard HT, and one documented case of virilization from a compounding clinic is a signal the unregulated market can cause real harm.

The question asks whether bioidentical hormones outperform standard hormone therapy in menopausal women. Of the records retrieved, most are about screen time in children, Müllerian agenesis, or other irrelevant topics. The only records that touch the topic at all are a 2021 case report of virilization from bioidentical hormones [1] and a 2015 study design paper for an FDA-approved product [2]—neither of which compares bioidentical to conventional therapy on clinical outcomes.

The REPLENISH paper describes a phase 3 trial of a manufacturer-funded product combining 17β-estradiol and natural progesterone [2]. But the evidence here is only the design, not results. No efficacy rates, no safety counts, no long-term data. A trial design with no results tells you nothing about whether the drug works or is safe.

What this retrieval does not contain matters more than what it does. Zero long-term studies compare bioidentical to conventional hormones on hard endpoints: heart disease, breast cancer, fractures, or dementia. The entire risk-benefit question that motivated the ask—whether body-identical hormones reduce the harms seen in the Women's Health Initiative—is untouched by the records here.

My call: the evidence does not support that bioidentical hormones work better than standard HT, and the case of virilization from a compounding clinic [1] is a real red flag that the unregulated market can deliver doses and ratios that cause harm. Confidence: low.